Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.

Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Eisel J, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger MC, Harter PN, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende C, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suvà ML, Niemeyer BA, von Deimling A, Wick W, Platten M.

Nat Med. 2018 Aug;24(8):1192-1203. doi: 10.1038/s41591-018-0095-6. Epub 2018 Jul 9.

PMID:
29988124
2.

Origin of Gliomas.

Cahill D, Turcan S.

Semin Neurol. 2018 Feb;38(1):5-10. doi: 10.1055/s-0037-1620238. Epub 2018 Mar 16.

PMID:
29548046
3.

Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence.

Turcan S, Makarov V, Taranda J, Wang Y, Fabius AWM, Wu W, Zheng Y, El-Amine N, Haddock S, Nanjangud G, LeKaye HC, Brennan C, Cross J, Huse JT, Kelleher NL, Osten P, Thompson CB, Chan TA.

Nat Genet. 2018 Jan;50(1):62-72. doi: 10.1038/s41588-017-0001-z. Epub 2017 Nov 27.

PMID:
29180699
4.

An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis.

Walsh LA, Alvarez MJ, Sabio EY, Reyngold M, Makarov V, Mukherjee S, Lee KW, Desrichard A, Turcan Ş, Dalin MG, Rajasekhar VK, Chen S, Vahdat LT, Califano A, Chan TA.

Cell Rep. 2017 Aug 15;20(7):1623-1640. doi: 10.1016/j.celrep.2017.07.052.

5.

IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation.

Oktay Y, Ülgen E, Can Ö, Akyerli CB, Yüksel Ş, Erdemgil Y, Durası IM, Henegariu OI, Nanni EP, Selevsek N, Grossmann J, Erson-Omay EZ, Bai H, Gupta M, Lee W, Turcan Ş, Özpınar A, Huse JT, Sav MA, Flanagan A, Günel M, Sezerman OU, Yakıcıer MC, Pamir MN, Özduman K.

Sci Rep. 2016 Jun 10;6:27569. doi: 10.1038/srep27569.

6.

Integrated genomic characterization of IDH1-mutant glioma malignant progression.

Bai H, Harmancı AS, Erson-Omay EZ, Li J, Coşkun S, Simon M, Krischek B, Özduman K, Omay SB, Sorensen EA, Turcan Ş, Bakırcığlu M, Carrión-Grant G, Murray PB, Clark VE, Ercan-Sencicek AG, Knight J, Sencar L, Altınok S, Kaulen LD, Gülez B, Timmer M, Schramm J, Mishra-Gorur K, Henegariu O, Moliterno J, Louvi A, Chan TA, Tannheimer SL, Pamir MN, Vortmeyer AO, Bilguvar K, Yasuno K, Günel M.

Nat Genet. 2016 Jan;48(1):59-66. doi: 10.1038/ng.3457. Epub 2015 Nov 30.

7.

Remodeling of the methylation landscape in breast cancer metastasis.

Reyngold M, Turcan S, Giri D, Kannan K, Walsh LA, Viale A, Drobnjak M, Vahdat LT, Lee W, Chan TA.

PLoS One. 2014 Aug 1;9(8):e103896. doi: 10.1371/journal.pone.0103896. eCollection 2014.

8.

Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins.

Gong Y, Zack TI, Morris LG, Lin K, Hukkelhoven E, Raheja R, Tan IL, Turcan S, Veeriah S, Meng S, Viale A, Schumacher SE, Palmedo P, Beroukhim R, Chan TA.

Nat Genet. 2014 Jun;46(6):588-94. doi: 10.1038/ng.2981. Epub 2014 May 4.

9.

Transcriptional diversity of long-term glioblastoma survivors.

Gerber NK, Goenka A, Turcan S, Reyngold M, Makarov V, Kannan K, Beal K, Omuro A, Yamada Y, Gutin P, Brennan CW, Huse JT, Chan TA.

Neuro Oncol. 2014 Sep;16(9):1186-95. doi: 10.1093/neuonc/nou043. Epub 2014 Mar 23.

10.

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

Turcan S, Fabius AW, Borodovsky A, Pedraza A, Brennan C, Huse J, Viale A, Riggins GJ, Chan TA.

Oncotarget. 2013 Oct;4(10):1729-36.

11.

5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.

Borodovsky A, Salmasi V, Turcan S, Fabius AW, Baia GS, Eberhart CG, Weingart JD, Gallia GL, Baylin SB, Chan TA, Riggins GJ.

Oncotarget. 2013 Oct;4(10):1737-47.

12.

MAPping the genomic landscape of low-grade pediatric gliomas.

Turcan S, Chan TA.

Nat Genet. 2013 Aug;45(8):847-9. doi: 10.1038/ng.2706.

13.

BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1.

Tönjes M, Barbus S, Park YJ, Wang W, Schlotter M, Lindroth AM, Pleier SV, Bai AHC, Karra D, Piro RM, Felsberg J, Addington A, Lemke D, Weibrecht I, Hovestadt V, Rolli CG, Campos B, Turcan S, Sturm D, Witt H, Chan TA, Herold-Mende C, Kemkemer R, König R, Schmidt K, Hull WE, Pfister SM, Jugold M, Hutson SM, Plass C, Okun JG, Reifenberger G, Lichter P, Radlwimmer B.

Nat Med. 2013 Jul;19(7):901-908. doi: 10.1038/nm.3217. Epub 2013 Jun 23.

14.

The mutational landscape of adenoid cystic carcinoma.

Ho AS, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N, Ramaswami D, Walsh LA, Eng S, Huse JT, Zhang J, Dolgalev I, Huberman K, Heguy A, Viale A, Drobnjak M, Leversha MA, Rice CE, Singh B, Iyer NG, Leemans CR, Bloemena E, Ferris RL, Seethala RR, Gross BE, Liang Y, Sinha R, Peng L, Raphael BJ, Turcan S, Gong Y, Schultz N, Kim S, Chiosea S, Shah JP, Sander C, Lee W, Chan TA.

Nat Genet. 2013 Jul;45(7):791-8. doi: 10.1038/ng.2643. Epub 2013 May 19.

15.

Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management.

Ho AS, Turcan S, Chan TA.

Onco Targets Ther. 2013;6:223-32. doi: 10.2147/OTT.S34680. Epub 2013 Mar 21.

16.

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, Chan TA, Graeber TG, Yen KE, Mellinghoff IK.

Science. 2013 May 3;340(6132):626-30. doi: 10.1126/science.1236062. Epub 2013 Apr 4.

17.

Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation.

Morris LG, Kaufman AM, Gong Y, Ramaswami D, Walsh LA, Turcan Ş, Eng S, Kannan K, Zou Y, Peng L, Banuchi VE, Paty P, Zeng Z, Vakiani E, Solit D, Singh B, Ganly I, Liau L, Cloughesy TC, Mischel PS, Mellinghoff IK, Chan TA.

Nat Genet. 2013 Mar;45(3):253-61. doi: 10.1038/ng.2538. Epub 2013 Jan 27.

18.

The cochlea as an independent neuroendocrine organ: expression and possible roles of a local hypothalamic-pituitary-adrenal axis-equivalent signaling system.

Basappa J, Graham CE, Turcan S, Vetter DE.

Hear Res. 2012 Jun;288(1-2):3-18. doi: 10.1016/j.heares.2012.03.007. Epub 2012 Mar 29. Review.

19.

IDH mutation impairs histone demethylation and results in a block to cell differentiation.

Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, Thompson CB.

Nature. 2012 Feb 15;483(7390):474-8. doi: 10.1038/nature10860.

20.

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.

Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A, Morris LG, Huse JT, Mellinghoff IK, Chan TA.

Nature. 2012 Feb 15;483(7390):479-83. doi: 10.1038/nature10866.

Supplemental Content

Loading ...
Support Center